VACCINE FOR THE PROPHYLAXIS AND TREATMENT OF ROTAVIRUS INFECTION WITH A FUSION PROTEIN AS ACTIVE AGENT (VARIANTS)

摘要

The group of inventions relates to molecular biology, biotechnology and medicine and is intended for the prophylaxis and treatment of rotavirus infection. Proposed is a vaccine against rotavirus infection which is based on a fusion protein consisting of immunogenic epitopes of the VP6 and VP8 proteins linked by a flexible bridge. Also proposed is a vaccine against rotavirus infection which is based on a fusion protein consisting of immunogenic epitopes of the VP6 and VP8 proteins and an adjuvant, namely flagellin fragments, linked by flexible bridges. The active ingredient of the vaccine is represented by six amino acid sequences (SEQ ID NO.: 1-SEQ ID NO.: 6). The active ingredient of the vaccine is produced in prokaryote and eukaryote cells using recombinant DNA technology and various purification methods. The fusion proteins are shown to be immunologically multivalent against rotavirus A, B and C. The proposed vaccines are shown to have a prophylactic and therapeutic effect. Using these vaccines will make it possible to provide universal protection for humans against rotaviruses.